04
Aug

Webinar: Drug Supply Chain Security Act: Legal Overview and Cross-Enterprise Compliance Strategies (August 11, 2020 @1:00-2:00 PM ET)

In 2019, FDA issued the first Warning Letter for violations of the Drug Supply Chain Security Act, signaling its heightened attention to supply chain and distribution issues. Since DSCSA was enacted in 2013, various provision have come into effect. It is important for companies not just to understand the law’s requirements, but also how to […]

Read More
03
Aug

Rebecca (Becky) Welton, new Senior Associate in the Regulatory Practice at Lachman Consultant Services, Inc.

We are pleased to announce that Rebecca Welton has accepted the position of Senior Associate in the Regulatory Practice at Lachman Consultants, effective August 3, 2020. Ms. Welton is an experienced Science, Operations and Regulatory leader with 25+ years in the pharmaceutical industry, holding positions of escalating accountabilities in chemistry, formulation, management, pilot plant, and […]

Read More
17
Jul

Mary Oates to Participate in Webinar on Virtual Inspections

On Tuesday, July 21, Mary Oates, Ph.D., Vice President, Compliance Services, will be participating in a webinar organized by Informa, publishers of the Pink Sheet and Scrip. Mary will be a panelist in a session on Virtual Drug Inspections, occurring at 2 PM EST. The entire webinar series, which is taking place over a 24 […]

Read More
29
Jun

STILL TIME TO REGISTER FOR “REMOTE AND VIRTUAL INSPECTIONS DURING THE COVID-19 PANDEMIC: REGULATOR PERSPECTIVES”

Globally, the COVID-19 pandemic has required changes in the way regulators worldwide have been approaching the inspection of manufacturing facilities. Please join us for a webinar presented by PDA sponsored by Lachman Consultants titled “Remote and Virtual Inspections during the COVID-19 Pandemic: Regulator Perspectives” on June 29 from 10 am-11:30 AM EST to gain some […]

Read More
24
Jun

“REMOTE AND VIRTUAL INSPECTIONS DURING THE COVID-19 PANDEMIC: REGULATOR PERSPECTIVES” – STILL TIME TO REGISTER!

Globally, the COVID-19 pandemic has required changes in the way regulators worldwide have been approaching the inspection of manufacturing facilities. Please join us for a webinar presented by PDA sponsored by Lachman Consultants titled “Remote and Virtual Inspections during the COVID-19 Pandemic: Regulator Perspectives” on June 29 from 10 am-11:30 AM EST to gain some […]

Read More
18
Jun

Recording available for webinar on Virtual Inspections

Lachman Consultants recently participated in a webinar with Arnold & Porter called “FDA Inspection Alternatives During the COVID-19 Pandemic: Requesting, Preparing for and Responding to FDA Virtual Inspections”. If you missed it, don’t despair – there is a recording of it, which can be found here. We hope you enjoy it, and look forward to “seeing” you at […]

Read More
17
Jun

Lachman Consultants to Sponsor PDA Webinar “Remote and Virtual Inspections during the COVID-19 Pandemic: Regulator Perspectives”

Globally, the COVID-19 pandemic has required changes in the way regulators worldwide have been approaching the inspection of manufacturing facilities. Please join us for a webinar presented by PDA sponsored by Lachman Consultants titled “Remote and Virtual Inspections during the COVID-19 Pandemic: Regulator Perspectives” on June 29 from 10 am-11:30 AM EST to gain some […]

Read More
08
Jun

WEBINAR: FDA Inspection Alternatives During the COVID-19 Pandemic: Requesting, Preparing for and Responding to FDA Virtual Inspections

Due to COVID-19 travel and safety concerns, the Food and Drug Administration has suspended most of its foreign and domestic inspections. In order to avoid delays in evaluating applications to market drugs, devices and biologics because of the lack of an in-person inspection, FDA has recognized the need to rely on alternatives, such as virtual […]

Read More
08
Jun

WEBINAR: FDA Inspection Alternatives During the COVID-19 Pandemic: Requesting, Preparing for and Responding to FDA Virtual Inspections

Due to COVID-19 travel and safety concerns, the Food and Drug Administration has suspended most of its foreign and domestic inspections. In order to avoid delays in evaluating applications to market drugs, devices and biologics because of the lack of an in-person inspection, FDA has recognized the need to rely on alternatives, such as virtual […]

Read More
04
May

New Webinar Series From Lachman Consultants Provides Valuable Information To The Pharmaceutical Industry

(Westbury, NY— April 2019) Lachman Consultant Services, Inc. (Lachman Consultants) will be launching a new webinar series beginning with “Preparing for and Handling an FDA Inspection” on Thursday, May 14th at 2:00 pm EDT. Ever a responsive and supportive partner to its clients, these webinars are Lachman Consultants latest effort in providing timely and critical […]

Read More
1 2 10